The recent online publication of findings from the University of Southern California ataxia working group called Enigma served to fuel more interest in the simmering drug development space of Friederichs’s ataxia (FRDA), where a handful of gene therapies and other approaches, plus one promising small-molecule treatment, are in the works.
Swanbio Therapeutics Inc. closed a $56 million series B round to take its lead gene therapy program, SBT-101, into clinical development later this year. The candidate, comprised of an adeno-associated virus type 9 vector encoding the ABCD1 peroxisomal ATP-binding cassette transporter, is in development for adrenomyeloneuropathy (AMN), an inherited disease that affects the central nervous system.
It was a patient-reported outcome, one that could actually be seen in the mirror, that alerted researchers they might be on track in their phase I/II study of cystinosis. The patient noticed that for the first time in his life his hair had become darker, like his brother’s. It was all because the rare disease inhibiting the pigment in his body was being impacted by the treatment. “It’s a secondary issue, but I find it fascinating,” Avrobio Inc.’s CEO, Geoff MacKay, told BioWorld. “When you run trials like this, you stumble upon some fascinating results.”
Kriya Therapeutics Inc. has raised a $270 million series C financing to further develop its pipeline of gene therapies for treating cancer, ophthalmological problems, and rare and chronic diseases. The Redwood City, Calif.-based company has greatly expanded its employee roster, from about seven people to around 160 people, since its $80 million series A in May 2020 and scaled its learning-enabled tech and cloud computing abilities. It also further solidified its technology, manufacturing, R&D, and therapeutics units, something it plans to continue with the series C money.
Although gene therapy is now “a clinical reality,” it still remains an early stage therapeutic modality. That’s the view of Caroline Man Xu, CEO and co-founder of Vigeneron GmbH, a German gene therapy company that has maintained a low profile while steadily staking out a promising position in gene therapies for inherited retinal disease.
For Kevin Friedman, the secret to making newly emergent Kelonia Therapeutics Inc. a success is reducing complexity and keeping everything as simple as possible. The Boston-based company just raised $50 million in series A funding to further its development of genetic medicines encompassing a range of diseases.
Through a $600 million deal, Juniper Biologics Pte. Ltd. has acquired rights from Kolon Life Science Inc. to develop and commercialize TG-C LD (Tissuegene-C low dose) for the treatment of knee osteoarthritis. Singapore-based Juniper will hold the rights for Asia Pacific, the Middle East and Africa and be responsible for developing and commercializing the candidate within those regions.
Through a $600 million deal, Juniper Biologics Pte. Ltd. has acquired rights from Kolon Life Science Inc. to develop and commercialize TG-C LD (Tissuegene-C low dose) for the treatment of knee osteoarthritis. Singapore-based Juniper will hold the rights for Asia Pacific, the Middle East and Africa and be responsible for developing and commercializing the candidate within those regions.
Actinium Pharmaceuticals Inc. is receiving an up-front $35 million with a possible $417 million in regulatory and commercial milestones in its new license and supply agreement with Immedica Pharma AB, of Stockholm. Immedica is getting the exclusive European, Middle Eastern and North African rights to Iomab-B, an antibody radiation conjugate comprising apamistamab, a CD45-targeting antibody, and the radioisotope iodine-131. Actinium is eligible for royalties in the mid-20% range on net sales.
Bluebird Bio Inc. became the latest in a spate of gene therapy firms to disclose restructuring plans, as the company aims to save $160 million over the next two years, saying goodbye to about a third of its workforce. It’s the other shoe to drop after Cambridge, Mass.-based Bluebird rattled Wall Street with phraseology in the firm’s fourth-quarter earnings report March 4 that expressed “substantial doubt” regarding whether operations could go on.
RSS
